A role for the cyclin box in the ubiquitin-mediated degradation of cyclin G1

Cancer Research

Volumn 68, Issue 14, 2008, Pages 5581-5590

  Piscopo, Denise M ^a   Hinds, Philip W ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN G1; PROTEIN MDM2; PROTEIN P53; PROTEIN SUBUNIT; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 1; CYCLIN G; CYCLINE; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; PROTEASOME; TP53 PROTEIN, HUMAN; UBIQUITIN;

ARTICLE; CELL CYCLE REGULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION; ADENOVIRUS; ANIMAL; CELL STRAIN 3T3; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; TUMOR CELL LINE;

ADENOVIRIDAE; ADP-RIBOSYLATION FACTOR 1; ANIMALS; CELL LINE, TUMOR; CYCLINS; GENE EXPRESSION REGULATION; HUMANS; MICE; NIH 3T3 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 48649092038     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6346     Document Type: Article

References (49)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
2. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-23.
3. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-908.
4. Corcoran CA, Huang Y, Sheikh MS. The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest. Cancer Biol Ther 2004;3:721-5.
5. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
6. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1checkpoint control. Cell 1995;82:675-84.
7. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003;1:993-1000.
8. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96-107.
9. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000;19:1473-6.
10. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003;302:1972-5.
11. Yu ZK, Geyer RK, Maki CG. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene 2000;19:5892-7.
12. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006;6:663-73.
13. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 1994;13:4816-22.
14. Zauberman A, Lupo A, Oren M. Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene 1995;10:2361-6.
15. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. [see comments]. Cell 1994;79:573-82.
16. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004;116:221-34.
17. Pastila R, Leszczynski D. Ultraviolet-A radiation induces changes in cyclin G gene expression in mouse melanoma B16-1 cells. Cancer Cell Int 2007;7:7.
18. Kang CM, Park KP, Song JE, et al. Possible biomarkers for ionizing radiation exposure in human peripheral blood lymphocytes. Radiat Res 2003;159:312-9.
19. Kanaoka Y, Kimura SH, Okazaki I, Ikeda M, Nojima H. GAK: a cyclin G associated kinase contains a tensin/auxilin-like domain. FEBS Lett 1997;402:73-80.
20. Ohtsuka T, Ryu H, Minamishima YA, Ryo A, Lee SW. Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene 2003;22:1678-87.
21. Zhao L, Samuels T, Winckler S, et al. Cyclin G1has growth inhibitory activity linked to the ARF-Mdm2-53 and pRb tumor suppressor pathways. Mol Cancer Res 2003;1:195-206.
22. Okamoto K, Kamibayashi C, Serrano M, Prives C, Mumby MC, Beach D. p53-Dependent association between cyclin G and the B′ subunit of protein phosphatase 2A. Mol Cell Biol 1996;16:6593-602.
23. Okamoto K, Li H, Jensen MR, et al. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell 2002;9:761-71.
24. Kimura SH, Nojima H. Cyclin G1associates with MDM2 and regulates accumulation and degradation of p53 protein. Genes Cells 2002;7:869-80.
25. Bennin DA, Don AS, Brake T, et al. Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B' subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest. J Biol Chem 2002;277:27449-67.
26. Kimura SH, Ikawa M, Ito A, Okabe M, Nojima H. Cyclin G1is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene 2001;20:3290-300.
27. Jensen MR, Factor VM, Fantozzi A, Helin K, Huh CG, Thorgeirsson SS. Reduced hepatic tumor incidence in cyclin G1-deficient mice. Hepatology 2003;37:862-70.
28. Baek WK, Kim D, Jung N, et al. Increased expression of cyclin G1in leiomyoma compared with normal myometrium. Am J Obstet Gynecol 2003;188:634-9.
29. Perez R, Wu N, Klipfel AA, Beart RW, Jr. A better cell cycle target for gene therapy of colorectal cancer: cyclin G. J Gastrointest Surg 2003;7:884-9.
30. Reimer CL, Borras AM, Kurdistani SK, et al. Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells. J Biol Chem 1999;274:11022-9.
31. Shimizu A, Nishida J, Ueoka Y, et al. CyclinG contributes to G2/M arrest of cells in response to DNA damage. Biochem Biophys Res Commun 1998;242:529-33.
32. Skotzko M, Wu L, Anderson WF, Gordon EM, Hall FL. Retroviral vector-mediated gene transfer of antisense cyclin G1( CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res 1995;55:5493-8.
33. Smith ML, Kontny HU, Bortnick R, Fornace AJ. The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Exp Cell Res 1997;230:61-8.
34. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A 1994;91:709-13.
35. Jeffrey PD, Russo AA, Polyak K, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex [see comments]. Nature 1995;376:313-20.
36. Tamura K, Kanaoka Y, Jinno S, et al. Cyclin G: a new mammalian cyclin with homology to fission yeast Cig1. Oncogene 1993;8:2113-8.
37. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996;10:1979-90.
38. Diehl JA, Sherr CJ. A dominant-negative cyclin D1m utant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol 1997;17:7362-74.
39. Won KA, Reed SI. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J 1996;15:4182-93.
40. Okamoto K, Prives C. A role of cyclin G in the process of apoptosis. Oncogene 1999;18:4606-15.
41. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
42. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000;275:8945-51.
43. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7.
44. Kubbutat MH, Ludwig RL, Levine AJ, Vousden KH. Analysis of the degradation function of Mdm2. Cell Growth Differ 1999;10:87-92.
45. Winston JT, Chu C, Harper JW. Culprits in the degradation of cyclin E apprehended. Genes Dev 1999;13:2751-7.
46. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3h regulates cyclin D1proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
47. Ceccarelli E, Mann C. A Cdc28 mutant uncouples G1 cyclin phosphorylation and ubiquitination from G1 cyclin proteolysis. J Biol Chem 2001;276:41725-32.
48. Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1990;1:571-80.
49. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.